Open AccessThe value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: A meta-analysis
Author(s) -
Chao Cui,
Xiaohong Sun,
Jun Zhang,
Dong Han,
Jun Gu
Publication year - 2014
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.145835
Subject(s) - diagnostic odds ratio , meta analysis , medicine , confidence interval , biomarker , odds ratio , likelihood ratios in diagnostic testing , lung cancer , gastroenterology , receiver operating characteristic , oncology , carcinoma , biochemistry , chemistry
The serum level of Cyfra21-1 was always elevated in patients with nonsmall cell lung carcinoma. The aim of this meta-analysis was to evaluate the serum Cyfra21-1 as a biomarker in the diagnosis of nonsmall cell lung cancer (NSCLC).